Bank of America has increased its stake in Fulcrum Therapeutics, Inc., now holding 1.5% of the company’s common stock. This change was revealed in a recent SEC filing, which underscores the ongoing shifts in ownership dynamics within the pharmaceutical preparations industry.

Fulcrum Therapeutics, Inc. is a company focused on developing innovative therapies for patients with genetically driven diseases. The company is classified under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. The firm trades on the Nasdaq under the ticker symbol FULC.

The recent filing, dated October 28, 2026, indicates that Bank of America now beneficially owns 1,114,867 shares of Fulcrum, with shared voting and dispositive power. The filing comments that this ownership calculation is based on the 76,297,257 outstanding shares reported in Fulcrum’s Form 10-Q filed on July 30, 2026.

According to the filing, Bank of America’s involvement is part of a broader strategy that may influence how Fulcrum Therapeutics operates moving forward. The filing states, "The beneficial ownership calculation relies on the 76,297,257 outstanding shares disclosed in the Form 10-Q by the issuer on July 30, 2026." This indicates a significant level of interest from a major financial institution, which could lead to increased scrutiny and support for Fulcrum’s initiatives.

This change in ownership may affect various stakeholders, including investors, analysts, and competitors within the pharmaceutical sector. As Bank of America is a prominent player in the finance industry, its involvement could enhance Fulcrum’s credibility and attract further investments.

The filing does not specify what actions may follow this change in ownership or whether there will be subsequent filings related to this matter.